60
Participants
Start Date
January 20, 2021
Primary Completion Date
March 31, 2029
Study Completion Date
March 31, 2029
STK-001
STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection.
NYU Comprehensive Epilepsy Center, New York
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Florida Hospital for Children, Orlando
Nicklaus Children's Hospital, Miami
UT LeBonheur Pediatric Specialists, Inc., Memphis
Michigan Medicine, Ann Arbor
University of Iowa Children's Hospital, Iowa City
Mayo Clinic, Rochester
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Cook Children's Medical Center, Fort Worth
Children's Hospital Colorado, Aurora
University of California San Francisco Medical Center, San Francisco
Oregon Health & Science University, Portland
Seattle Children's Hospital, Seattle
MultiCare Health System Institute for Research and Innovation, Tacoma
Massachusetts General Hospital, Boston
Stoke Therapeutics, Inc
INDUSTRY